CN107683138A - 取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉类化合物的用途 - Google Patents

取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉类化合物的用途 Download PDF

Info

Publication number
CN107683138A
CN107683138A CN201680022080.8A CN201680022080A CN107683138A CN 107683138 A CN107683138 A CN 107683138A CN 201680022080 A CN201680022080 A CN 201680022080A CN 107683138 A CN107683138 A CN 107683138A
Authority
CN
China
Prior art keywords
bases
quinazoline
morpholine
propoxyl group
methoxyl groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680022080.8A
Other languages
English (en)
Chinese (zh)
Inventor
刘宁姝
C.佩纳
M.杰弗斯
I.让夫雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Bayer Healthcare LLC
Original Assignee
Bayer Pharma AG
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Healthcare LLC filed Critical Bayer Pharma AG
Publication of CN107683138A publication Critical patent/CN107683138A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201680022080.8A 2015-03-09 2016-03-07 取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉类化合物的用途 Pending CN107683138A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562130547P 2015-03-09 2015-03-09
US62/130547 2015-03-09
PCT/EP2016/054728 WO2016142313A1 (en) 2015-03-09 2016-03-07 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines

Publications (1)

Publication Number Publication Date
CN107683138A true CN107683138A (zh) 2018-02-09

Family

ID=55484986

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680022080.8A Pending CN107683138A (zh) 2015-03-09 2016-03-07 取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉类化合物的用途

Country Status (18)

Country Link
US (1) US20180042929A1 (cg-RX-API-DMAC7.html)
EP (1) EP3268005A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018512403A (cg-RX-API-DMAC7.html)
KR (1) KR20180013850A (cg-RX-API-DMAC7.html)
CN (1) CN107683138A (cg-RX-API-DMAC7.html)
AU (1) AU2016231260A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017019190A2 (cg-RX-API-DMAC7.html)
CA (1) CA2978807A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017002284A1 (cg-RX-API-DMAC7.html)
EA (1) EA201791975A1 (cg-RX-API-DMAC7.html)
HK (1) HK1250645A1 (cg-RX-API-DMAC7.html)
IL (1) IL254168A0 (cg-RX-API-DMAC7.html)
MA (1) MA43840A (cg-RX-API-DMAC7.html)
MX (1) MX2017011607A (cg-RX-API-DMAC7.html)
PH (1) PH12017501644A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201707239WA (cg-RX-API-DMAC7.html)
TN (1) TN2017000385A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016142313A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111500587A (zh) * 2020-04-15 2020-08-07 湖南省科域生物医药科技有限公司 Pgr作为治疗子宫内膜异位症的产品中的用途及其检测pgr的试剂盒

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
AP2015008750A0 (en) 2013-04-08 2015-09-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EA201791974A1 (ru) 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин
WO2017153220A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CA3068324A1 (en) * 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
EP4143569B1 (en) * 2020-05-01 2026-07-29 Mayo Foundation for Medical Education and Research Methods for treating endometrial cancer
WO2022140467A1 (en) * 2020-12-21 2022-06-30 Samson Pharma, Llc Topical compositions and methods of treating skin diseases and conditions with such compositions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007030360A2 (en) * 2005-09-07 2007-03-15 Laboratoires Serono S.A. P13k inhibitors for the treatment of endometriosis
WO2008070150A1 (en) * 2006-12-05 2008-06-12 Bayer Schering Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2011128407A2 (en) * 2010-04-16 2011-10-20 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
WO2012136553A1 (en) * 2011-04-05 2012-10-11 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2014191938A1 (en) * 2013-05-31 2014-12-04 Novartis Ag Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007030360A2 (en) * 2005-09-07 2007-03-15 Laboratoires Serono S.A. P13k inhibitors for the treatment of endometriosis
WO2008070150A1 (en) * 2006-12-05 2008-06-12 Bayer Schering Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2011128407A2 (en) * 2010-04-16 2011-10-20 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
WO2012136553A1 (en) * 2011-04-05 2012-10-11 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2014191938A1 (en) * 2013-05-31 2014-12-04 Novartis Ag Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ELLEN STELLOO等: "Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative", 《MODERN PATHOLOGY》 *
NINGSHU LIU等: "BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110a and p110d Activities in Tumor Cell Lines and Xenograft Models", 《MOLECULAR CANCER THERAPEUTICS》 *
RAMEZ N ESKANDER等: "Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies", 《EXPERT REVIEW OF CLINICAL PHARMACOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111500587A (zh) * 2020-04-15 2020-08-07 湖南省科域生物医药科技有限公司 Pgr作为治疗子宫内膜异位症的产品中的用途及其检测pgr的试剂盒

Also Published As

Publication number Publication date
MA43840A (fr) 2018-11-21
SG11201707239WA (en) 2017-10-30
JP2018512403A (ja) 2018-05-17
BR112017019190A2 (pt) 2018-04-24
MX2017011607A (es) 2018-04-10
CA2978807A1 (en) 2016-09-15
WO2016142313A1 (en) 2016-09-15
HK1250645A1 (zh) 2019-01-11
EA201791975A1 (ru) 2018-03-30
KR20180013850A (ko) 2018-02-07
TN2017000385A1 (en) 2019-01-16
PH12017501644A1 (en) 2018-03-12
US20180042929A1 (en) 2018-02-15
CL2017002284A1 (es) 2018-05-18
AU2016231260A1 (en) 2017-09-21
EP3268005A1 (en) 2018-01-17
IL254168A0 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
TWI689307B (zh) 經取代之2,3-二氫咪唑并[1,2-c]喹唑啉之用途
CN107864625B (zh) 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品
AU2017203474B2 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
JP2018512403A (ja) 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリン類の使用
TW201249847A (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JP7280286B2 (ja) びまん性大細胞型b細胞リンパ腫を治療するための5-フルオロ-4-(4-フルオロ-2-メトキシフェニル)-n-{4-[(s-メチルスルホンイミドイル)メチル]ピリジン-2-イル}ピリジン-2-アミンの使用
US11185549B2 (en) Combination of a PI3K-inhibitor with an androgen receptor antagonist
TW201625261A (zh) 4-(4-氟-2-甲氧苯基)-n-{3-[(s-甲磺醯亞胺醯基)甲基]苯基}-1,3,5-三-2-胺於治療白血病之用途
TW201642866A (zh) 4-(4-氟-2-甲氧苯基)-n-{3-[(s-甲基磺醯亞胺醯基)甲基]苯基}-1,3,5-三-2-胺於治療淋巴癌之用途
TW201642865A (zh) 4-(4-氟-2-甲氧苯基)-n-{3-[(s-甲基磺醯亞胺醯基)甲基]苯基}-1,3,5-三-2-胺於治療胃癌之用途
HK1220121B (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
US20160045496A1 (en) Use of (rs)-s-cyclopropyl-s-(4--5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treatment of specific tumours
HK1194995A (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1250645

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180209

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1250645

Country of ref document: HK